华检医疗(01931.HK)与内地创新生物科技公司订合作协议
华检医疗(01931.HK)公布,於今年3月8日公司与独立第三方Boxin订立合作协议,公司获Boxin独家委聘为战略夥伴,在中国成立数间医疗测试中心,Boxin应付的总财政预算约2亿元人民币,可由订约方另行协定作出调整。公司亦负责采购及安装医疗测试中心的设备及设施。
合作协议自该协议日期起计为期五年。Boxin将於合作协议年期内分期向公司支付代价。Boxin为创新生物科技公司,从事HIV抗药性测试及治疗,总部设於中国。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.